SDG, Inc. is a privately held developer of bio-nanotechnologies for use in drug delivery systems and in consumer product applications. The Company's patented systems have been used in the creation and development of novel oral delivery systems for insulin, interferon and other protein-based therapies, cell-receptor targeting of a wide variety of large and small molecule drugs and diagnostics, and consumer products ranging from hair conditioners and styling agents to skin-adhering insect repellents and sunscreens. These systems are ideally suited for use as cell receptor targeted vehicles in personalized medicine strategies for cancer. SDG's technologies have been tested in more than four hundred human subjects and have been shown to be both safe and efficacious in various disease categories, including diabetes and hepatitis.